West Pharmaceutical Services, Inc.


SKU: WST-1 Category:


West Pharmaceutical Services delivered mixed results for the previous quarter, with revenues below the analyst consensus. However, it managed to exceed the earnings expectations of Wall Street. Their net sales were $753.8 million, a 2.5% fall in organic sales. Sales price increases provided $43.1 million or 5.6 percentage points of growth in the quarter. The base Proprietary goods business expanded by the mid-teens and was the main driver of the second quarter achievement. The biologics market unit once more experienced double-digit growth with steady demand. As the base increased strongly by double digits, the company’s Generics market unit continued to profit from HVP capacity additions. Additionally, the Pharma market’s unit base expanded by high single digits. The quarter also saw substantial progress for contract manufacturing due to the delivery of parts for injection-related devices. Furthermore, West Pharmaceutical continues collaborating closely with customers to update short- and long-term demand trends. These trends highlight the significance of the company’s capacity investments, which substantially impact West’s global operations.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!